- Home
- EONR vs QNTM Comparison
EONR vs QNTM Comparison
Compare EONR & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EONR
- QNTM
- Stock Information
- Founded
- EONR 2017
- QNTM 1998
- Country
- EONR United States
- QNTM Canada
- Employees
- EONR N/A
- QNTM N/A
- Industry
- EONR
- QNTM
- Sector
- EONR
- QNTM
- Exchange
- EONR NYSE
- QNTM NYSE
- Market Cap
- EONR 7.8M
- QNTM 8.7M
- IPO Year
- EONR N/A
- QNTM N/A
- Fundamental
- Price
- EONR $0.39
- QNTM $9.15
- Analyst Decision
- EONR Strong Buy
- QNTM
- Analyst Count
- EONR 1
- QNTM 0
- Target Price
- EONR $4.50
- QNTM N/A
- AVG Volume (30 Days)
- EONR 317.4K
- QNTM 101.1K
- Earning Date
- EONR 05-23-2025
- QNTM 05-06-2025
- Dividend Yield
- EONR N/A
- QNTM N/A
- EPS Growth
- EONR N/A
- QNTM N/A
- EPS
- EONR N/A
- QNTM N/A
- Revenue
- EONR $20,269,293.00
- QNTM N/A
- Revenue This Year
- EONR $46.94
- QNTM N/A
- Revenue Next Year
- EONR $64.38
- QNTM N/A
- P/E Ratio
- EONR N/A
- QNTM N/A
- Revenue Growth
- EONR N/A
- QNTM N/A
- 52 Week Low
- EONR $0.35
- QNTM $2.70
- 52 Week High
- EONR $3.15
- QNTM $25.35
- Technical
- Relative Strength Index (RSI)
- EONR N/A
- QNTM 62.27
- Support Level
- EONR N/A
- QNTM $7.96
- Resistance Level
- EONR N/A
- QNTM $9.45
- Average True Range (ATR)
- EONR 0.00
- QNTM 0.72
- MACD
- EONR 0.00
- QNTM 0.10
- Stochastic Oscillator
- EONR 0.00
- QNTM 90.00
About EONR EON RESOURCES INC
EON Resources Inc is an independent upstream energy company focused on maximizing total returns to its shareholders through the development of onshore oil and natural gas properties in the United States. Its current focus is as an upstream energy company producing oil and gas properties in the Permian Basin.
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.